Breast cancer breakthrough? new study tests skipping surgery for early lesions
NCT ID NCT07245316
First seen Jan 04, 2026 · Last updated May 30, 2026 · Updated 19 times
Summary
This study looks at whether women with certain non-invasive breast conditions (like atypical ductal hyperplasia or ductal carcinoma in situ) can safely avoid surgery and instead take hormone-blocking medication (endocrine therapy) for 5 years. The goal is to see if this approach keeps breast cancer from coming back in the same breast. The study involves 340 women aged 35 and older whose biopsy shows hormone-sensitive, HER2-negative cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCTAL CARCINOMA IN SITU OF THE BREAST are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
Seoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.